Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None2025202420232022202120202019201820172016 March 11, 2025 Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors February 26, 2025 Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis February 26, 2025 Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis February 21, 2025 Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference February 12, 2025 Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 January 13, 2025 Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra January 3, 2025 Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Madrigal press releases are available below. Search them by keyword or browse by date. Year None2025202420232022202120202019201820172016 March 11, 2025 Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors February 26, 2025 Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis February 26, 2025 Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis February 21, 2025 Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference February 12, 2025 Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 January 13, 2025 Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra January 3, 2025 Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
February 26, 2025 Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
February 26, 2025 Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
February 21, 2025 Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
February 12, 2025 Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
January 13, 2025 Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
January 3, 2025 Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
